Orexin-A (Hypocretin-1)

Orexin-A (also known as hypocretin-1) is a 33-amino acid neuropeptide produced by a small cluster of approximately 70,000 neurons in the lateral hypothalamus. It was independently discovered in 1998 by two research groups: Masashi Yanagisawa's team named the peptides "orexins" (from the Greek "orexis" meaning appetite), while Luis de Lecea's group named them "hypocretins" (hypothalamic secretin-like peptides). Orexin-A, along with orexin-B, is derived from a single precursor protein, prepro-orexin.

Orexin-A acts on two G-protein coupled receptors: OX1R (selective for orexin-A) and OX2R (responsive to both orexin-A and orexin-B). Despite the relatively small number of orexin-producing neurons, their projections extend widely throughout the brain, innervating arousal-promoting centers including the locus coeruleus, dorsal raphe, tuberomammillary nucleus, and basal forebrain. This widespread innervation pattern reflects orexin's role as a master regulator of wakefulness and behavioral state.

The most significant clinical discovery related to orexins is that narcolepsy type 1 (with cataplexy) is caused by the autoimmune destruction of orexin-producing neurons, resulting in profound orexin deficiency. Narcolepsy patients have undetectable or very low cerebrospinal fluid orexin-A levels (< 110 pg/mL), and this measurement has become a diagnostic biomarker. This discovery has driven interest in orexin replacement therapy for narcolepsy, though delivery challenges (orexin peptides do not readily cross the blood-brain barrier) remain obstacles.

The pharmaceutical industry has successfully targeted the orexin system for insomnia treatment through dual orexin receptor antagonists (DORAs). Suvorexant (Belsomra) and lemborexant (Dayvigo) are FDA-approved insomnia medications that block orexin signaling to promote sleep. Conversely, orexin-2 receptor agonists are being developed as wake-promoting agents for narcolepsy and excessive daytime sleepiness, with several candidates in clinical trials.